Novotech

Join Novotech at the Veeva Korea Summit 2024, one of the largest events in the pharmaceutical and biotechnology industry in the region on October 15, 2024, at the Grand Intercontinental Seoul Parnas. This event will bring together professionals from R&D in clinical, manufacturing, licensing, and pharmacovigilance to sales, medical, and marketing, to learn about the latest industry trends, expert insights, and customer innovation in the industry. SangHee Kim, Country Managing Director of Novotech Korea, will serve as a panelist for the session “𝙃𝙤𝙬 𝙛𝙖𝙧 𝙝𝙖𝙨 𝙩𝙝𝙚 𝙆𝙤𝙧𝙚𝙖𝙣 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙩𝙧𝙞𝙖𝙡 𝙞𝙣𝙙𝙪𝙨𝙩𝙧𝙮 𝙘𝙤𝙢𝙚 𝙞𝙣 𝙞𝙩𝙨 𝙙𝙞𝙜𝙞𝙩𝙖𝙡 𝙩𝙧𝙖𝙣𝙨𝙛𝙤𝙧𝙢𝙖𝙩𝙞𝙤𝙣?”. During this session, SangHee will share her insights on the advantages of digitalization, offer practical experiences, and discuss key challenges that lie ahead in advancing digital transformation within the industry. The panel discussion will take place from 1:30 pm - 2:30 pm as part of the Afternoon Sessions 1 program. Don’t miss out on this impactful discussion! #Novotech #Veeva #CRO

Press Pause and Recharge Take an extended unpaid leave to pursue personal interests or responsibilities. We support your need for rejuvenation and work-life balance. Follow us to learn more at Novotech #lifeatnovotech #cra #clinicaltrials #clinicalresearch #clinicalresearchassociate #cro

#DidYouKnow Cell and gene therapies are projected to grow at an annual rate of 36% through 2030? These therapies are playing an increasingly important role in healthcare by offering personalized treatment options for diseases that were previously difficult or impossible to treat. As part of the precision medicine approach, they target the underlying genetic causes of disease. Novotech’s 2024 Cell & Gene Therapy Global Clinical Trial Landscape report provides an in-depth overview of the state of cell and gene therapies, with a focus on innovations like CAR-T and CAR-NK therapies, particularly in the areas of cancer and rare genetic disorders. The report also examines global trends, including the Asia-Pacific region’s role in driving faster patient recruitment and clinical trial growth. These therapies represent a key development in the ongoing effort to advance treatment options for conditions such as hematologic cancers and rare genetic diseases. https://lnkd.in/dDYfXS8z #Novotech #GenTherapy #ClinicalTrials

We’re pleased to announce that Dr. David Ng, Vice President of Global Biometrics at Novotech, will be a featured speaker at the 16th Annual Outsourcing in Clinical Trials New England event, taking place October 23 - 24, 2024 at the Westin Boston Seaport, in Boston, Massachusetts. With over 30 years of expertise in data management, statistics, and regulatory interactions, Dr. Ng will offer his insights on Biometrics Considerations in Implementing New Technology. 🔹 When: October 24, 9:30 AM EDT 🔹 Where: Stream B We look forward to the opportunity to connect with you at the event. https://lnkd.in/dr6GtTgB #OCTNE2024 #Novotech #Biometrics

The discovery of microRNA has been recognized by the 2024 Nobel Prize in Physiology or Medicine, jointly awarded to Victor Ambros and Gary Ruvkun. This discovery reveals a critical layer of post-transcriptional gene regulation. MicroRNAs (miRNA) can finely tune protein production by binding to messenger RNAs, inhibiting or degrading them, thereby preventing diseases like cancer and genetic disorders. With over 1,000 miRNAs identified in humans, these therapies hold promise for precise, targeted treatments, enhancing the future of personalized medicine. While their research into microRNA began in 1993, medical science has since shown that microRNA therapies have incredible potential by offering a novel mechanism for regulating gene expression, with many promising therapies leveraging this knowledge. Novotech’s report on RNA therapies includes several examples of microRNA therapies currently in development, and is available for free download: https://lnkd.in/dXtvcJp6 #Novotech #mRNA #NobePrize2024

The 2024 SAPA Annual Conference held at the Hyatt Regency New Brunswick, NJ on September 27-28 was a successful and productive event for Novotech. With the theme "Redefining Medicine, Navigating Resilience, Transforming Lives," the conference convened leading biotech leaders from both the U.S. and China to explore innovative solutions in pharmaceutical development, and explore how East-West collaborations can enhance efficiencies and expand capabilities within the sector. Scott Schliebner, Novotech's VP of Drug Development Consulting, contributed to the panel discussion on "Global Solutions for Developing Transformative Medicine". His insights into How Best to Develop Innovative Medicines for Patients Around the Globe were invaluable! We were also delighted to engage with many of you at our booth and during one-on-one meetings, and hope to see you all again in the near future. https://lnkd.in/dRdkZaiZ Angela Wang, Scott Schliebner #SAPA2024 #ClinicalDevelopment #InnovativeMedicines

Thank you to all who attended our recent webinar, "Empowering Patients to Overcome Challenges in Orphan Drug Development". This insightful session offered valuable perspectives for stakeholders in the biotech sector, particular those focused on rare disease and orphan drug development. Novotech would like to thank panelists Afshawn C. (Director, Program Management, Avidity Biosciences, Inc.), Michal Meller (Director, Project Management, Novotech), Lauren Dahl (Senior Operations Manager, leapcure), and Ella Balasa (Patient Advocate, Consultant, Balasa Consulting) for their valuable insights into critical strategies for enhancing patient engagement, overcoming operational challenges, and strengthening collaboration between sponsors, CROs, and patient advocacy groups. Thanks also go to Scott Schliebner, VP of Clinical Development Consulting at Novotech for his excellent moderation and for guiding such an informative discussion. If you were unable to attend the on-demand recording is now available for viewing https://lnkd.in/dJ3hiB5s #OrphanDrugs #RareDisease

#DidYouKnow that Cervical Cancer (CC) is the 8th most diagnosed and 9th leading cause of cancer mortality in the world? With over 660,000 new cases and almost 350,000 deaths in 2022, cervical cancer remains a significant global health issue, particularly in regions like Asia and Africa. Early detection, vaccination, and screening remain crucial in curbing these numbers. Since 2019, more than 1,300 clinical trials have been initiated globally, with the Asia-Pacific region leading in trial activity. Novotech’s comprehensive report on Cervical Cancer provides a thorough analysis of the current treatment landscape and research developments in this field, while also highlighting existing and projected trends in funding and research efforts related to Cervical Cancer. Download this free report https://lnkd.in/dRFp8fcp #CervicalCancer #ClinicalTrials #OncologyResearch

Novotech is proud to have been a Featured Sponsor at Outsourcing in Clinical Trials (OCT) Southern California in San Diego last week. A special thank you to everyone who stopped by to connect with our team! Congratulations to Sarah Rose Anderson, our Therapeutic Strategy Director, for her insightful contributions during the panel discussion on "The Clinical Trial Landscape for Small to Mid-Sized Biopharma in Southern California" as well as her own presentation “Do you have the right oncology sites in a competitive market?” The feedback was overwhelmingly positive, with the attendees describing the panel “Wonderfully interactive and insightful.” See you again next year! https://lnkd.in/d-RWTDvD Rod Bugawan, PharmD, Craig Leach #OCT #ClinicalTrials #Novotech

Join us as Peter Legget shares his inspiring journey from CRA to his current role as Clinical Systems Training Lead. Discover how Novotech's commitment to groundbreaking clinical research and positive patient outcomes has fueled Peter's passion for his work. Learn about the memorable moments that have shaped his career, the impact of his contributions, and how Novotech's supportive environment has fostered his professional growth across multiple departments. #lifeatnovotech #novostories #CRA #clinicaltrials